B02BD02 • moroctocog alfa • Blood and blood forming organs | Vitamin k and other hemostatics | Blood coagulation factors
Moroctocog alfa is a medication used for the treatment and prevention of bleeding episodes in patients with hemophilia A. It is a recombinant form of coagulation factor VIII, essential for blood clotting.
The medication is administered intravenously and is indicated for both the treatment of acute bleeding episodes and long-term prophylaxis. It is effective in reducing the frequency of bleeding episodes and preventing associated complications.
Side effects may include headache, fever, injection site reactions, or, in rare cases, severe allergic reactions. It is important to monitor factor VIII levels and follow your doctor's instructions.
Consult your doctor to discuss the benefits and risks of treatment with Moroctocog alfa. Regular monitoring is essential to ensure the therapy's effectiveness.
Substance: moroctocog alfa
Date of last drug list: 01-06-2024
Commercial code: W61059001
Concentration: 250UI
Pharmaceutical form: powder+solution for injection
Quantity: 1
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).